Brooks Labs board approves 1:1 demerger of Manufacturing Business into Abridge

Demerger ratio announcedCore business divestedStrategic Transactions View source PDF Explain this filing

BROOKS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.1%Reaction day

₹68.73

prior close

₹69.15

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.6%+3.8% vs market

On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.0

10m

+1.8

15m

+2.5

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+2.1-1.6+3.8

Next day

-2.5-1.0-1.6

-4.6-2.6-2.0

-12.7-5.1-7.6

-12.0-6.1-5.9

-15.2-8.3-6.9

-13.5-6.4-7.1

15d

———

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Brooks Labs board approved a scheme to demerge its Manufacturing Business (Baddi facility, 96.66 percent of FY26 turnover at Rs. 8,287.26 lakhs) into wholly-owned subsidiary Abridge Speciality Limited. Share entitlement ratio is 1:1 with no cash consideration. Abridge will seek listing on BSE and NSE. Post-scheme, Abridge will be renamed Brooks Laboratories Limited and current entity will become Xuri Lifesciences Limited. Each platform expected to have about Rs. 50 crore for growth. Listing targeted in about 16 months, subject to NCLT, SEBI, stock exchange and shareholder approvals.

Likely market impact

Shareholders get 1 Abridge share for every Brooks Labs share held on record date. Subject to multiple approvals over about 16 months.